Abstract
Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases. We examine current research focusing on identifying ligands that are dual and pan-PPAR agonists, selective PPAR-γ modulators, PPAR-β/δ agonists and that are of natural origin.
Keywords: Cardiometabolic syndrome, diabetes mellitus, herbal and traditional natural medicines, peroxisome proliferator-activated receptor-γ
Current Molecular Pharmacology
Title:Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs)
Volume: 5
Author(s): Tom Hsun-Wei Huang and Basil D. Roufogalis
Affiliation:
Keywords: Cardiometabolic syndrome, diabetes mellitus, herbal and traditional natural medicines, peroxisome proliferator-activated receptor-γ
Abstract: Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases. We examine current research focusing on identifying ligands that are dual and pan-PPAR agonists, selective PPAR-γ modulators, PPAR-β/δ agonists and that are of natural origin.
Export Options
About this article
Cite this article as:
Hsun-Wei Huang Tom and D. Roufogalis Basil, Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs), Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020241
DOI https://dx.doi.org/10.2174/1874467211205020241 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelial Therapy of Atherosclerosis and its Risk Factors
Current Vascular Pharmacology Treating Obesity: Pharmacology of Energy Expenditure
Current Drug Targets The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Recent Patents in Diagnosis and Treatment for Inborn Errors of Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry The Association of Fractalkine Receptor (T280M) Polymorphism in the Pathogenesis of Acute Coronary Syndrome in the Egyptian Population
Current Pharmaceutical Biotechnology Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology Editorial (Thematic Issue: Controversies and Current Approaches in the Diagnosis of Prediabetes and Diabetes Mellitus)
Current Diabetes Reviews An Update in Incretin-Based Therapy: A Focus on Dipeptidyl Peptidase - 4 Inhibitors
Current Diabetes Reviews Pathophysiology of Preeclampsia and Possible Role of Zinc in its Genesis
Current Women`s Health Reviews The Dual Role of Free Fatty Acid Signaling in Inflammation and Therapeutics
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Synergistic Effects of d-Chiro-Inositol and Manganese on Blood Glucose and Body Weight of Streptozotocin-Induced Diabetic Rats
Current Bioactive Compounds MiR-137 Restricts the Viability and Migration of HTR-8/SVneo Cells by Downregulating FNDC5 in Gestational Diabetes Mellitus
Current Molecular Medicine Human Recombinant Leptin Administration as a Potential Obesity Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Possible Roles of Reg Family Proteins in Pancreatic Islet Cell Growth
Endocrine, Metabolic & Immune Disorders - Drug Targets Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Effect of Danggui-Shaoyao-San-Containing Serum on the Renal Tubular Epithelial-Mesenchymal Transition of Diabetic Nephropathy
Current Pharmaceutical Biotechnology Screening of Early and Late Onset Alzheimer’s Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy
Current Alzheimer Research Reduction in Estimated Glomerular Filtration Rate (eGFR) Results in an Increased Risk of Spontaneous Hemorrhagic Transformation in Patients with Large-artery Atherosclerosis Stroke
Current Neurovascular Research